Loading…
JAMP FINASTERIDE is a brand name for Finasteride, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: JAMP Finasteride Tablets (finasteride tablets) is a Type II 5α-reductase inhibitor, indicated for: • the treatment of male pattern hair loss (androgenetic alopecia) in men who have mild to moderate scalp hair loss of the vertex and anterior mid-scalp. Clinical studies were conducted in men between 18 to 41 years of…
Verbatim from this product's HC label. Tap a section to expand.
). 1%). (See 8 ADVERSE REACTIONS). 5% placebo). 5α- reductase inhibitors may increase the risk of development of high-grade prostate cancer. Whether the effect of 5α-reductase inhibitors to reduce prostate volume, or study-related factors, impacted the results of these studies has not been established.
5 ng / mL at Month 12. Further, in clinical studies with PROSCAR® (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%. Other studies with PROSCAR® showed it may also cause decreases in serum PSA in the presence of prostate cancer.
These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride. Any confirmed increase from the lowest PSA value while on finasteride tablets may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α- reductase inhibitor.
Non-compliance to therapy with finasteride tablets may also affect PSA test results. Psychiatric There have been post-marketing reports of serious psychiatric symptoms in patients being treated with finasteride that sometimes continued after treatment discontinuation.
5 Post-Market Adverse Reactions). It is recommended that all patients be screened for suicidal ideation, self-harm, and depression and / or associated risk factors before treatment initiation. Product Monograph JAMP Finasteride Tablets (Finasteride Tablets) Page 7 of 27 Clinical monitoring of all patients for signs and symptoms of psychiatric disorder should continue throughout treatment and after.
If these occur, treatment should be discontinued and patients advised to seek medical advice, as soon as possible. 1 Pregnant Women JAMP Finasteride Tablets is not indicated for use in women. Women should not handle crushed or broken JAMP Finasteride Tablets when they are or may potentially be pregnant (see 2 CONTRAINDICATIONS).
Because of the ability of Type II 5α-reductase inhibitors such as finasteride to inhibit conversion of testosterone to dihydrotestosterone, JAMP Finasteride Tablets may cause abnormalities of the external genitalia of a male fetus when administered to a pregnant woman.
Exposure to Finasteride - Risk to Male Fetus:
and 14 CLINICAL TRIALS). 2 Geriatrics (> 65 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use (see 14 CLINICAL TRIALS). 1 Prengnant Women, Exposure to Finasteride - Risk to Male Fetus); • Hypersensitivity to any component of this product.
JAMP Finasteride Tablets is not indicated for use in women or children. 4. 2 Recommended Dose and Dosage Adjustment The recommended dosage is one 1 mg tablet daily. JAMP Finasteride Tablets may be taken with or without food. In general, daily use for three months or more is necessary before hair growth is increased and / or further hair loss is prevented.
Continued use is recommended to obtain maximum benefit. Withdrawal of treatment leads to reversibility of effect within 12 months. 15 mL / s [9 mL / min]) as pharmacokinetic studies did not indicate any change in the disposition of finasteride.
4 Administration JAMP Finasteride Tablets is for oral administration. 5 Missed Dose If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual. 5 OVERDOSAGE Patients have received single doses of finasteride up to 400 mg and multiple doses of finasteride up to 80 mg / day for three months without adverse reactions.
For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1- 844-764-7669). 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 1 – Dosage Forms, Strengths, Composition and Packaging Route of Administration Dosage Form / Strength / Composition Non-medicinal Ingredients oral Tablet/1 mg Docusate sodium, hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized maize starch, sodium starch glycolate, talc and titanium dioxide.
JAMP
1 Prengnant Women, Exposure to Finasteride - Risk to Male Fetus); • Hypersensitivity to any component of this product. JAMP Finasteride Tablets is not indicated for use in women or children. 4. 2 Recommended Dose and Dosage Adjustment The recommended dosage is one 1 mg tablet daily.
JAMP Finasteride Tablets may be taken with or without food. In general, daily use for three months or more is necessary before hair growth is increased and / or further hair loss is prevented. Continued use is recommended to obtain maximum benefit.
Withdrawal of treatment leads to reversibility of effect within 12 months. 15 mL / s [9 mL / min]) as pharmacokinetic studies did not indicate any change in the disposition of finasteride. 4 Administration JAMP Finasteride Tablets is for oral administration.
5 Missed Dose If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual. 5 OVERDOSAGE Patients have received single doses of finasteride up to 400 mg and multiple doses of finasteride up to 80 mg / day for three months without adverse reactions.
For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1- 844-764-7669). 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 1 – Dosage Forms, Strengths, Composition and Packaging Route of Administration Dosage Form / Strength / Composition Non-medicinal Ingredients oral Tablet/1 mg Docusate sodium, hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized maize starch, sodium starch glycolate, talc and titanium dioxide.
JAMP Finasteride Tablets is a tan coloured, 8-sided, film-coated convex tablet debossed with “FS” on one side and “1” on the other side. Available in blister packs of 30 tablets and bottles of 100 tablets. 7 WARNINGS AND PRECAUTIONS General Caution should be used in the administration of JAMP Finasteride Tablets in patients with liver Product Monograph JAMP Finasteride Tablets (Finasteride Tablets) Page 6 of 27 function abnormalities, as finasteride is metabolized in the liver.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Finasteride in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Women should not handle crushed or broken tablets of JAMP Finasteride Tablets when they are or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. JAMP Finasteride Tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.
2 Breast-feeding It is not known whether JAMP Finasteride Tablets is excreted in human milk. 3 Pediatrics (<18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 14 CLINICAL TRIALS).
4 Geriatrics (>65 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use (see 14 CLINICAL TRIALS).
Use in Postmenopausal Women:
Results of a one year placebo-controlled study, enrolling 137 healthy postmenopausal women with androgenetic alopecia (age range: 41-60 years), showed no benefit of treatment with finasteride tablets daily on scalp hair growth. 2 Clinical Trial Adverse Reactions Clinical trials are conducted under very specific conditions.
The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.
Finasteride for male pattern hair loss has been evaluated for safety in clinical studies involving more than 3,200 men and is generally well tolerated. In three 12-month, placebo-controlled, double-blind, multicenter studies of comparable design, the overall safety profiles of finasteride tablets and placebo were similar.
1% of 934 men treated with placebo. In these studies, the following drug-related adverse reactions were […]
JAMP Finasteride Tablets is a tan coloured, 8-sided, film-coated convex tablet debossed with “FS” on one side and “1” on the other side. Available in blister packs of 30 tablets and bottles of 100 tablets. 7 WARNINGS AND PRECAUTIONS General Caution should be used in the administration of JAMP Finasteride Tablets in patients with liver Product Monograph JAMP Finasteride Tablets (Finasteride Tablets) Page 6 of 27 function abnormalities, as finasteride is metabolized in the liver.
Other causes of alopecia should be ruled out prior to prescribing JAMP Finasteride Tablets. Efficacy and duration of treatment should be assessed periodically by the treating physician. Physicians should instruct their patients to promptly report any changes in their breasts such as lumps, pain or nipple discharge.
Breast changes including breast enlargement, tenderness and neoplasm have been reported (see
Other causes of alopecia should be ruled out prior to prescribing JAMP Finasteride Tablets. Efficacy and duration of treatment should be assessed periodically by the treating physician. Physicians should instruct their patients to promptly report any changes in their breasts such as lumps, pain or nipple discharge.
Breast changes including breast enlargement, tenderness and neoplasm have been reported (see 8 ADVERSE REACTIONS). 1%). (See 8 ADVERSE REACTIONS). 5% placebo). 5α- reductase inhibitors may increase the risk of development of high-grade prostate cancer.
Whether the effect of 5α-reductase inhibitors to reduce prostate volume, or study-related factors, impacted the results of these studies has not been established. 5 ng / mL at Month 12. Further, in clinical studies with PROSCAR® (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.
Other studies with PROSCAR® showed it may also cause decreases in serum PSA in the presence of prostate cancer. These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.
Any confirmed increase from the lowest PSA value while on finasteride tablets may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α- reductase inhibitor.
Non-compliance to therapy with finasteride tablets may also affect PSA test results. Psychiatric There have been post-marketing reports of serious psychiatric symptoms in patients being treated with finasteride that sometimes continued after treatment discontinuation.
5 Post-Market Adverse Reactions). It is recommended that all patients be screened for suicidal ideation, self-harm, and depression and / or associated risk factors before treatment initiation. Product Monograph JAMP Finasteride Tablets (Finasteride Tablets) Page 7 of 27 Clinical monitoring of all patients for signs and symptoms of psychiatric disorder should continue throughout treatment and after.
If these occur, treatment should be discontinued and patients advised to seek medical advice, as soon as possible. 1 Special Populations […]